Atomo Diagnostics Ltd (AT1) - Net Assets

Latest as of December 2025: AU$6.64 Million AUD ≈ $4.70 Million USD

Based on the latest financial reports, Atomo Diagnostics Ltd (AT1) has net assets worth AU$6.64 Million AUD (≈ $4.70 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$9.48 Million ≈ $6.71 Million USD) and total liabilities (AU$2.84 Million ≈ $2.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Atomo Diagnostics Ltd (AT1) total liabilities for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$6.64 Million
% of Total Assets 70.09%
Annual Growth Rate 86.42%
5-Year Change -76.81%
10-Year Change N/A
Growth Volatility 3837.19

Atomo Diagnostics Ltd - Net Assets Trend (2017–2025)

This chart illustrates how Atomo Diagnostics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore AT1 asset base for the complete picture of this company's asset base.

Annual Net Assets for Atomo Diagnostics Ltd (2017–2025)

The table below shows the annual net assets of Atomo Diagnostics Ltd from 2017 to 2025. For live valuation and market cap data, see market value of Atomo Diagnostics Ltd.

Year Net Assets Change
2025-06-30 AU$6.98 Million
≈ $4.94 Million		 -30.83%
2024-06-30 AU$10.08 Million
≈ $7.14 Million		 -31.82%
2023-06-30 AU$14.79 Million
≈ $10.47 Million		 -40.40%
2022-06-30 AU$24.81 Million
≈ $17.56 Million		 -17.53%
2021-06-30 AU$30.09 Million
≈ $21.29 Million		 -12.74%
2020-06-30 AU$34.48 Million
≈ $24.40 Million		 +730.18%
2019-06-30 AU$-5.47 Million
≈ $-3.87 Million		 -11.93%
2018-06-30 AU$-4.89 Million
≈ $-3.46 Million		 -10322.88%
2017-06-30 AU$47.82K
≈ $33.83K		 --

Equity Component Analysis

This analysis shows how different components contribute to Atomo Diagnostics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5179835600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$71.84 Million 1029.82%
Other Comprehensive Income AU$91.75K 1.32%
Total Equity AU$6.98 Million 100.00%

Atomo Diagnostics Ltd Competitors by Market Cap

The table below lists competitors of Atomo Diagnostics Ltd ranked by their market capitalization.

Company Market Cap
Bayhorse Silver Inc
V:BHS
 $13.76 Million
Grupo Televisa SAB DRC
BA:TV
 $13.77 Million
Vogiatzoglou Systems S.A
AT:VOSYS
 $13.79 Million
LZ Technology Holdings Limited Class B Ordinary Shares
NASDAQ:LZMH
 $13.80 Million
Immo-Zenobe Gramme SA
BR:ZEN
 $13.76 Million
BIT MINING C.A SP.ADR 100
F:50C0
 $13.76 Million
Elysee Development Corp
V:ELC
 $13.76 Million
Hamelin Gold Ltd
AU:HMG
 $13.75 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Atomo Diagnostics Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 10,084,619 to 6,975,816, a change of -3,108,803 (-30.8%).
  • Net loss of 4,970,934 reduced equity.
  • New share issuances of 1,652,838 increased equity.
  • Other comprehensive income increased equity by 3,349.
  • Other factors increased equity by 205,944.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-4.97 Million -71.26%
Share Issuances AU$1.65 Million +23.69%
Other Comprehensive Income AU$3.35K +0.05%
Other Changes AU$205.94K +2.95%
Total Change AU$- -30.83%

Book Value vs Market Value Analysis

This analysis compares Atomo Diagnostics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.23x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 281.51x to 2.23x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-06-30 AU$0.00 AU$0.02 x
2018-06-30 AU$-0.01 AU$0.02 x
2019-06-30 AU$-0.01 AU$0.02 x
2020-06-30 AU$0.10 AU$0.02 x
2021-06-30 AU$0.05 AU$0.02 x
2022-06-30 AU$0.04 AU$0.02 x
2023-06-30 AU$0.03 AU$0.02 x
2024-06-30 AU$0.02 AU$0.02 x
2025-06-30 AU$0.01 AU$0.02 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Atomo Diagnostics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -71.26%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -131.08%
  • • Asset Turnover: 0.41x
  • • Equity Multiplier: 1.33x
  • Recent ROE (-71.26%) is above the historical average (-1226.98%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2017 -10766.62% -1745.65% 0.02x 248.20x AU$-5.15 Million
2018 0.00% -1705.89% 0.04x 0.00x AU$-4.41 Million
2019 0.00% -936.59% 0.09x 0.00x AU$-4.51 Million
2020 -26.73% -171.70% 0.15x 1.05x AU$-12.67 Million
2021 -20.01% -89.66% 0.21x 1.07x AU$-9.03 Million
2022 -23.00% -46.26% 0.46x 1.07x AU$-8.19 Million
2023 -67.33% -391.46% 0.15x 1.11x AU$-11.44 Million
2024 -67.90% -167.57% 0.36x 1.13x AU$-7.86 Million
2025 -71.26% -131.08% 0.41x 1.33x AU$-5.67 Million

Industry Comparison

This section compares Atomo Diagnostics Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $68,431,096
  • Average return on equity (ROE) among peers: -37.61%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Atomo Diagnostics Ltd (AT1) AU$6.64 Million -10766.62% 0.43x $13.76 Million
4DMEDICAL Ltd (4DX) $64.24 Million -46.81% 0.48x $1.63 Billion
Adherium Ltd (ADR) $-4.76 Million 0.00% 0.00x $7.37 Million
Aroa Biosurgery Ltd (ARX) $6.92 Million -23.35% 0.08x $150.91 Million
Avita Medical Inc (AVH) $5.12 Million -224.74% 0.50x $132.15 Million
Anteris Technologies Global Corp (AVR) $22.64 Million -106.07% 0.18x $570.83 Million
Control Bionics Ltd (CBL) $5.05 Million -38.22% 0.07x $18.95 Million
Cardiex Ltd (CDX) $4.88 Million 56.04% 0.31x $13.23 Million
Compumedics Ltd (CMP) $8.51 Million 8.89% 1.37x $41.70 Million
Cochlear Ltd (COH) $503.28 Million 35.79% 0.47x $4.60 Billion

About Atomo Diagnostics Ltd

AU:AT1 Australia Medical Devices
Market Cap
$13.76 Million
AU$19.44 Million AUD
Market Cap Rank
#26049 Global
#1222 in Australia
Share Price
AU$0.02
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.04
All Time High
AU$0.57
Categories
Companies in Australia Medical Devices
About

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.